Mehdi Yousefi | Immunology and Microbiology | Best Researcher Award

Prof. Mehdi Yousefi | Immunology and Microbiology | Best Researcher Award

Professsor at Tabriz University of Medical Sciences, Iran

Prof. Mehdi Yousefi, Associate Professor of Immunology at Tabriz University of Medical Sciences, is a distinguished researcher with an exceptional track record in immunology, reproductive immunology, autoimmune diseases, and cancer immunotherapy. With over a decade of academic and research experience, Prof. Yousefi has published extensively in high-impact journals, earning a Scopus H-index of 58 and a Google Scholar H-index of 71, placing him among the top 1% of highly cited researchers globally. His innovative contributions include several patents on human antibody fragments and advanced biomedical tools, reflecting his strong focus on translational research. Prof. Yousefi has been recognized multiple times as a Top Researcher by Tabriz University of Medical Sciences and has received the prestigious national Razi Award. Through his leadership, collaborative research, and commitment to advancing immunological science, Prof. Yousefi has made significant contributions to both basic and applied biomedical research, enhancing the scientific community’s understanding of immune-related diseases.

Professional Profile 

Education

Prof. Mehdi Yousefi has a strong and distinguished educational background in medical sciences, particularly in immunology. He earned his Bachelor’s degree (B.Sc.) in Medical Laboratory Technology from Tehran University of Medical Sciences in 2004, where he demonstrated academic excellence. He continued his studies at the same university, completing his Master’s degree (M.Sc.) in Immunology in 2007, where he ranked first in the national entrance exam for the program. Building on his passion for immunological research, Prof. Yousefi pursued a PhD in Immunology, also at Tehran University of Medical Sciences, and graduated in 2013 with the highest possible score (20 out of 20). His PhD research focused on humoral immune responses against tetanus toxin at the single-cell level, showcasing his expertise in immunological techniques and innovative approaches to studying immune mechanisms. His consistent academic excellence, top rankings, and commitment to scientific research laid a strong foundation for his successful career in immunology and medical sciences.

Professional Experience

Prof. Mehdi Yousefi has built an impressive professional career rooted in both academic excellence and cutting-edge research. Since 2013, he has served as an academic and research member at the Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, where he currently holds the position of Associate Professor of Immunology. His professional focus spans a wide range of areas, including reproductive immunology, autoimmune diseases, rheumatic disorders, and cancer immunotherapy. Prof. Yousefi has played a pivotal role in mentoring students, leading collaborative research projects, and contributing to the development of advanced immunological diagnostics and therapies. His innovative work has resulted in numerous patents, particularly in the field of antibody fragment development and cancer targeting, demonstrating his ability to bridge fundamental science with clinical applications. Through his leadership, prolific publications, and active participation in the scientific community, Prof. Yousefi has established himself as a respected and influential figure in immunology research.

Research Interest

Prof. Mehdi Yousefi’s research interests focus on understanding the complex mechanisms of the immune system and its role in health and disease. His primary areas of interest include reproductive immunology, where he investigates the immune system’s involvement in pregnancy complications and maternal-fetal tolerance. He also conducts extensive research on autoimmune diseases and rheumatic disorders, aiming to uncover the immunopathological mechanisms driving these conditions to develop more targeted therapies. In addition, Prof. Yousefi has a strong focus on cancer immunotherapy, particularly the development of novel antibody fragments and immunomodulatory approaches for treating cancers such as breast and colorectal cancer. His work also extends to neurosciences, where he explores the immune system’s interactions with the nervous system in neuroinflammatory and neurodegenerative diseases. Through his multidisciplinary approach, combining basic immunology, translational research, and clinical applications, Prof. Yousefi aims to advance immunological knowledge and develop innovative diagnostic and therapeutic strategies for immune-related disorders.

Award and Honor

Prof. Mehdi Yousefi has received numerous prestigious awards and honors, recognizing his outstanding contributions to immunology and biomedical research. He has been repeatedly honored as the Top Researcher at Tabriz University of Medical Sciences in 2014, 2015, 2017, 2020, and 2021, reflecting his consistent excellence in scientific output and impactful research projects. In 2020, he was further recognized at the national level with the prestigious Razi Award, one of the highest honors for medical research in Iran. In 2022, Prof. Yousefi’s global impact was highlighted when he was named among the Top 1% Highly Cited Researchers (ESI), a distinction that underscores the international significance and influence of his publications. These accolades, combined with his numerous patents and his leadership in innovative research projects, demonstrate Prof. Yousefi’s dedication, creativity, and commitment to advancing immunological science, both within Iran and on the global stage.

Research skill

Prof. Mehdi Yousefi possesses a diverse and advanced set of research skills that have enabled him to excel in the fields of immunology, molecular biology, and translational medicine. His expertise includes designing and conducting immunological assays, such as flow cytometry, ELISA, and cell culture techniques, which he applies to study immune responses in conditions ranging from autoimmune diseases to cancer immunotherapy. He has extensive experience in monoclonal antibody development, including phage display technology for the generation of scFv antibody fragments, which has led to several patents. Prof. Yousefi is also skilled in molecular techniques, such as PCR, gene cloning, and gene expression analysis, which he applies to study immune signaling pathways and immune cell interactions. His collaborative approach, combined with strong project management and scientific writing skills, has resulted in numerous high-impact publications and successful research collaborations, making him a well-rounded and innovative researcher in the field of immunology.

Conclusion

His exceptional publication record, high citation impact, consistent institutional and national awards, and innovative patented research make him a top candidate. His breadth of expertise, from immunology to translational medicine, and his proven track record of impactful research across various fields position him strongly for this recognition

Publications Top Noted

  • The effect of vitamin D supplementation and vaginal probiotics on fertility in women with recurrent implantation failure: A randomized clinical trial
    Authors: Badihi E., Sharifi P., Kamrani A., Aghebati-Maleki L., Yousefi M.
    Journal: Human Immunology
    Year: 2025
    Citations: 0

  • Impact of lymphocyte immunotherapy (LIT) on fertility rates in recurrent pregnancy loss (RPL) women with antinuclear antibodies: A randomized clinical trial
    Authors: Dashti M., Kamrani A., Shahir-Khajeh Z., Mehdizadeh A., Yousefi M.
    Journal: Journal of Reproductive Immunology
    Year: 2025
    Citations: 0

  • Intradermal lymphocyte therapy: A promising treatment for recurrent pregnancy loss in patients without anti-TPO antibodies
    Authors: Ebrahimi R., Asghari K.M., Alamdary S.J., Hojjat-Farsangi M., Yousefi M.
    Journal: Human Immunology
    Year: 2025
    Citations: 0

  • The role of probiotics in restoring the Th1 to Th2 ratio in women experiencing recurrent implantation failure; a double-blind randomized clinical trial
    Authors: Kamrani A., Asghari K.M., Zafarani Y., Zolfaghari M.A., Yousefi M.
    Journal: Human Immunology
    Year: 2025
    Citations: 0

  • Investigating the effect of echinacea extraction syrup on the outcomes of lower respiratory infections in patients with COVID-19: a randomized clinical trial study
    Authors: Kheirandish E., Mahdizadeh M., Mahdizadeh M., Yousefi M., Shojaee S.S.R.
    Journal: Virology Journal
    Year: 2024
    Citations: 0

  • Cyclosporine and fedratinib combination therapy via modulating Th17/Treg balance in Rat model of membranous glomerulonephritis
    Authors: Ghassabi A., Hosseini M., Abdoli Goungormaz H., Etemadi J., Yousefi M.
    Journal: Biochemistry and Biophysics Reports
    Year: 2024
    Citations: 0

  • The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alpha
    Authors: Sadeghi M., Moslehi A., Kheiry H., Movassaghpuor A.A., Niaragh F.J.
    Journal: Cancer Cell International
    Year: 2024
    Citations: 2

  • Evaluation of changes in exhausted T lymphocytes and miRNAs expression in the different trimesters of pregnancy in pregnant women
    Authors: Shekarchi A.A., Hosseini L., Kamrani A., Ahmadian Heris J., Yousefi M.
    Journal: Molecular Biology Reports
    Year: 2024
    Citations: 0

  • Revolutionized attitude toward recurrent pregnancy loss and recurrent implantation failure based on precision regenerative medicine
    Authors: Asghari K.M., Novinbahador T., Mehdizadeh A., Zolfaghari M.A., Yousefi M.
    Journal: Heliyon
    Year: 2024
    Citations: 0

  • Analysis of Th17 cell population and expression of microRNA and factors related to Th17 in patients with premature ovarian failure
    Authors: Nouri N., Aghebati-Maleki L., Zangbar M.S.S., Chakari-Khiavi F., Yousefi M.
    Journal: Journal of Reproductive Immunology
    Year: 2024
    Citations: 2

Dhanji Rajani | Immunology and Microbiology | Best Researcher Award

Dr. Dhanji Rajani | Immunology and Microbiology | Best Researcher Award

Microbiologist at Microcare laboratory and Tuberculosis research centre, India

Dr. Dhanji Popatbhai Rajani is a distinguished microbiologist with nearly two decades of experience in medical microbiology and diagnostics. He has made significant contributions to tuberculosis (TB) research, including evaluating innovative PCR tests for MDR TB and developing non-invasive, low-cost rapid diagnostics under prestigious government-funded projects like IMPRINT. With over 106 research publications and 24 patents, his work spans green synthesis, drug discovery, and sustainable methodologies. Dr. Rajani has received accolades such as the Best Performance Award for TB diagnosis from Surat Municipal Corporation in 2015 and 2016, highlighting his impact on public health. Currently leading diagnostics at Microcare Lab & TRC, he combines clinical expertise with research innovation. His leadership roles and commitment to advancing microbiology through cutting-edge research, sustainable practices, and impactful diagnostics establish him as a leading figure in his field, making him an exceptional candidate for recognition like the Best Researcher Award.

Professional Profile 

Education

Dr. Dhanji Popatbhai Rajani has a solid academic foundation in microbiology and medical diagnostics. He earned his Bachelor of Science (B.Sc) in Microbiology from the Sir P. P. Institute of Science in 2000, followed by a Postgraduate Diploma in Medical Laboratory Technology (PGDMLT) from K. K. Jani Paramedical Institute in 2001, which honed his technical expertise in laboratory sciences. Dr. Rajani further advanced his academic qualifications with a Master of Science (M.Sc) in Medical Microbiology from the Aditya Vikram Birla Post Graduate Institute in 2003, focusing on clinical and diagnostic microbiology. His academic journey culminated in a Ph.D. in Medical Microbiology from Bhavnagar University in 2012, where he specialized in advanced research methodologies and innovative diagnostics. This comprehensive education has laid the groundwork for his impactful career in microbiology, driving significant advancements in diagnostic research, particularly in tuberculosis and sustainable medical innovations.

Professional Experience

Dr. Dhanji Popatbhai Rajani has an extensive professional career in microbiology, marked by leadership roles and impactful contributions to clinical diagnostics. Since 2004, he has served as a Microbiologist at Microcare Lab & TRC, where he has led diagnostic and research initiatives, particularly in tuberculosis (TB) and other infectious diseases. From 2009 to 2013, he was the Chief Microbiologist at Smt. R. B. Shah Mahavir Hospital, where he spearheaded clinical diagnostic services and strengthened laboratory operations. With nearly two decades of experience, Dr. Rajani has established himself as a leader in medical microbiology, combining hands-on diagnostic expertise with cutting-edge research. His work has not only advanced TB diagnostics but also contributed to sustainable and innovative practices in microbiology. Dr. Rajani’s professional journey reflects a blend of clinical excellence, research innovation, and leadership, making him a pivotal figure in his field.

Research Interest

Dr. Dhanji Popatbhai Rajani’s research interests lie at the intersection of medical microbiology, innovative diagnostics, and sustainable scientific methodologies. He is deeply committed to advancing tuberculosis (TB) diagnostics, focusing on developing non-invasive, cost-effective, and rapid diagnostic tools that address global health challenges. His work also includes exploring green synthesis methods, such as using natural catalysts, to create sustainable and environmentally friendly processes in drug development. Dr. Rajani’s research encompasses the design and biological evaluation of novel compounds with antifungal, antimalarial, and antitubercular properties, integrating advanced techniques like molecular docking, ADME-Tox analysis, and pharmacophore modeling. With a keen interest in sustainable innovations, he has also contributed to the synthesis of bioactive compounds using eco-friendly methods. Dr. Rajani’s multidisciplinary approach reflects his commitment to improving public health through groundbreaking research and sustainable solutions, positioning him as a leader in medical microbiology and diagnostics.

Award and Honor

Dr. Dhanji Popatbhai Rajani has been recognized for his outstanding contributions to medical microbiology and diagnostics through several prestigious awards and honors. He received the Best Performance Award for TB diagnosis from the Surat Municipal Corporation in both 2015 and 2016, acknowledging his excellence in advancing tuberculosis diagnostics and public health impact. These accolades highlight his dedication to combating TB through innovative diagnostic solutions and his commitment to improving healthcare outcomes. Dr. Rajani’s work has garnered widespread appreciation for its relevance and effectiveness in addressing critical challenges in infectious disease management. These honors underscore his ability to translate research into practical applications, benefiting communities and setting new standards in diagnostic microbiology. With his achievements and consistent recognition, Dr. Rajani has established himself as a leading figure in his field, making significant strides in medical innovation and public health.

Conclusion

Dr. Dhanji Popatbhai Rajani is a strong candidate for the Best Researcher Award due to his extensive contributions to medical microbiology, particularly in TB diagnostics and drug synthesis. His robust portfolio of research papers, patents, and awards, combined with leadership in impactful projects, underscores his eligibility. Strengthening international collaboration and diversifying research impact would further elevate his profile for future recognition.

Publications Top Noted

  • Title: Synthesis of benzimidazolyl-1, 3, 4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents
    Authors: RV Patel, PK Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2012
    Citation: 191
  • Title: Synthesis and identification of β-aryloxyquinolines and their pyrano [3, 2-c] chromene derivatives as a new class of antimicrobial and antituberculosis agents
    Authors: DC Mungra, MP Patel, DP Rajani, RG Patel
    Year: 2011
    Citation: 161
  • Title: A strategic approach to the synthesis of functionalized spirooxindole pyrrolidine derivatives: in vitro antibacterial, antifungal, antimalarial and antitubercular studies
    Authors: S Haddad, S Boudriga, TN Akhaja, JP Raval, F Porzio, A Soldera, M Askri, DP Rajani
    Year: 2015
    Citation: 112
  • Title: Synthesis and studies of novel 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(quinoline-4-yloxy)-6-(piperazinyl/piperidinyl)-s-triazines as potential antimicrobial agents
    Authors: RV Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2011
    Citation: 109
  • Title: Synthesis of coumarin-based 1,3,4-oxadiazol-2ylthio-N-phenyl/benzothiazolyl acetamides as antimicrobial and antituberculosis agents
    Authors: RV Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2013
    Citation: 105
  • Title: Antimicrobial, Anti-TB, Anticancer and Anti-HIV Evaluation of New s-Triazine-Based Heterocycles
    Authors: RV Patel, P Kumari, DP Rajani, C Pannecouque, E De Clercq, KH Chikhalia
    Year: 2012
    Citation: 79
  • Title: New 2-benzylsulfanyl-nicotinic acid based 1, 3, 4-oxadiazoles: Their synthesis and biological evaluation
    Authors: NB Patel, AC Purohit, DP Rajani, R Moo-Puc, G Rivera
    Year: 2013
    Citation: 76
  • Title: Hydroxyl alkyl ammonium ionic liquid assisted green and one-pot regioselective access to functionalized pyrazolodihydropyridine core and their pharmacological evaluation
    Authors: DM Patel, MG Sharma, RM Vala, I Lagunes, A Puerta, JM Padrón, DP Rajani
    Year: 2019
    Citation: 72
  • Title: Synthesis, characterization and pharmacological activities of 2-[4-cyano-(3-trifluoromethyl) phenyl amino)]-4-(4-quinoline/coumarin-4-yloxy)-6-(fluoropiperazinyl)-s-triazines
    Authors: RV Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2011
    Citation: 68
  • Title: A Practical Green Visit to the Functionalized [1,2,4]Triazolo[5,1‐b]quinazolin‐8(4H)one Scaffolds Using the Group‐Assisted Purification (GAP) Chemistry and Their Biological Evaluation
    Authors: DM Patel, RM Vala, MG Sharma, DP Rajani, HM Patel
    Year: 2019
    Citation: 65
  • Title: Synthesis and evaluation of new chalcones, derived pyrazoline and cyclohexenone derivatives as potent antimicrobial, antitubercular and antileishmanial agents
    Authors: V Monga, K Goyal, M Steindel, M Malhotra, DP Rajani, SD Rajani
    Year: 2014
    Citation: 64
  • Title: Green approach for synthesis of bioactive Hantzsch 1, 4-dihydropyridine derivatives based on thiophene moiety via multicomponent reaction
    Authors: MG Sharma, DP Rajani, HM Patel
    Year: 2017
    Citation: 57